TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02901236

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Guarded Trabeculectomy
Description: A fornix based conjunctival peritomy is performed. A partial thickness scleral flap is dissected. Then trabeculectomy is performed with a Kelly's punch. A surgical iridectomy is performed. The scleral flap is secured with two pre-placed 8-0 Vicryl sutures (Ethicon, Somerville, NJ). The anterior chamber (AC) is inflated with balanced salt solution and suture tension is adjusted. Finally, conjunctiva is closed with 10-0 running Nylon sutures (Ethicon, Somerville, NJ). Patients receive a subconjunctival injection of 0.4 ml dexamethasone (4 mg/ml) and of 0.4 ml gentamicin (40 mg/ml) at the end of the case. Adjuvant pharmacologic treatment to prevent episcleral fibrosis and failure of the procedure is applied according to treatment arm assignment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Guarded Trabeculectomy
Description: A fornix based conjunctival peritomy is performed. A partial thickness scleral flap is dissected. Then trabeculectomy is performed with a Kelly's punch. A surgical iridectomy is performed. The scleral flap is secured with two pre-placed 8-0 Vicryl sutures (Ethicon, Somerville, NJ). The anterior chamber (AC) is inflated with balanced salt solution and suture tension is adjusted. Finally, conjunctiva is closed with 10-0 running Nylon sutures (Ethicon, Somerville, NJ). Patients receive a subconjunctival injection of 0.4 ml dexamethasone (4 mg/ml) and of 0.4 ml gentamicin (40 mg/ml) at the end of the case. Adjuvant pharmacologic treatment to prevent episcleral fibrosis and failure of the procedure is applied according to treatment arm assignment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: Sponges soaked in 0.02% mitomycin C (MMC) will be applied on bare sclera for 2 minutes. Subsequently, the area will be copiously irrigated with balanced salt solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: After conjunctival closure 1.25mg of bevacizumab will be injected into the anterior chamber through a paracentesis created earlier during the case.
Study: NCT04055415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adipose derived mesenchymal stem cells
Description: The MSCs of 1×10\*6/kg will be given in Central venous catheterization for injection at a total 100 ml (2) the experimental group was treated with conventional drug and adipose mesenchymal stem cell injection, and adipose MSCs were treated with central venous catheterization. The injection cycle was once every week of two times.Injection dose: 1×106 /kg.

Intervention type: DRUG
Group type: OTHER
Intervention: Conventional drug therapy（expectorant，bronchodilator）
Description: Conventional drug therapy（expectorant，bronchodilator）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional drug therapy（expectorant，bronchodilator）
Description: Conventional drug therapy（expectorant，bronchodilator）
Study: NCT02762305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RSVP Bone Builders Group Exercise
Study: NCT03359226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submandibular gland biopsy
Description: Needle biopsies of the right and left submandibular glands
Study: NCT03913689

Intervention type: DEVICE
Intervention: StimRouter Neuromodulation System
Description: An implantable neuromodulation device that treats chronic peripheral nerve pain.
Study: NCT01789619

Intervention type: DRUG
Intervention: Extended release tacrolimus (Advagraf®)
Study: NCT03231332

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microbiome Diversity detection
Description: detection of microbiome composition and detection of specific mutations in genes conferring resistance to antibiotics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microbiome Diversity detection
Description: detection of microbiome composition and detection of specific mutations in genes conferring resistance to antibiotics
Study: NCT00934414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin Inhalation Powder
Description: 30U

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin Inhalation Powder
Description: 30U
Study: NCT00890799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shanghai pmVSD occluder
Description: Ventricular Septal Defects Occluders with sizes from 4mm to 20mm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Patient in this group received open surgical repair of pmVSD.
Study: NCT01086384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/GW642444
Description: Combination inhaled corticosteroid and long-acting beta2-agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Description: Inhaled corticosteroid
Study: NCT01264445

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted GSK investigational HIV vaccine formulation 1
Description: Receive at Months 0 and 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted GSK investigational HIV vaccine formulation 2
Description: Receive at Months 0 and 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35 investigational HIV vaccine
Description: Receive at Month 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted GSK investigational HIV vaccine formulation 2
Description: Receive at Months 3 and 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted GSK investigational HIV vaccine formulation 2
Description: Receive at Months 0, 1, and 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35 investigational HIV vaccine
Description: Receive at Month 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35 investigational HIV vaccine
Description: Receive at Month 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35 investigational HIV vaccine
Description: Receive at Months 0, 1, and 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: (Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: (Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: (Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: (Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)
Study: NCT02834936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib
Study: NCT01037062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablet, P.O. 0.5, 1 mg, once daily
Study: NCT02592499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HM III

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OMM, optimal medical management
Description: Patients randomized to OMM will be treated according to international guidelines. All patients should receive a beta blocker, an ACE-inhibitor or an Angiotension II receptor blocker, and a mineralocorticoid receptor antagonist if tolerated and at optimally titrated doses according to guidelines. Loop diuretics should also be used as needed to control fluid retention. Other drugs that may relieve symptoms and improve prognosis can be used (incl ivabradin, digoxin, hydralazine,isosorbiddinitrate, anticoagulant agents). Patients that have an indication for implantable cardioverter defibrillator (ICD) and/or cardiac resynchronization therapy (CRT) should receive such therapy. Surgical interventions that may be indicated for specific underlying or contributing causes of heart failure.
Study: NCT04400344

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03644524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heat therapy
Description: Regular hot tub use
Study: NCT00519064

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted influenza vaccine
Study: NCT04626271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACR | U.S. Urine Analysis Test System
Description: Each study participant will test their urine sample using the ACR \| U.S. test device - a home-use device intended for the semi-quantitative measurement of ACR in the urine (albumin and creatinine ratio) and used to aid in the management of kidney health.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: URiSCAN Optima Urine Analyzer
Description: Upon completion of the test using the ACR \| U.S. device, each urine sample will be provided to a professional user for further urine analysis test using the comparator device, the URiSCAN Optima Urine Analyzer.
Study: NCT01658904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Study: NCT00427999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study: NCT03807453

Intervention type: OTHER
Intervention: Microbiota
Description: The scalp microbiota

Intervention type: OTHER
Intervention: Microbiota
Description: The scalp microbiota

Intervention type: OTHER
Intervention: Microbiota
Description: The scalp microbiota

Intervention type: OTHER
Intervention: Microbiota
Description: The scalp microbiota

Intervention type: OTHER
Intervention: Microbiota
Description: The scalp microbiota
Study: NCT02637856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Participants will receive an additional single 600-mg dose IV infusion at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)
Study: NCT04307641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 Page Information Sheet
Description: 2 page information sheet about medication abortion
Study: NCT02216578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Oral
Study: NCT00904683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2062430
Description: 400 mg intravenously (IV) every 4 weeks for 80 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenously (IV) every 4 weeks for 80 weeks
Study: NCT02238964

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strattice™ Reconstructive Tissue Matrix
Description: The protocol preference is for the mesh to be placed intra-peritoneally fashion (i.e. below the peritoneum). Anchoring bites will be taken in four to six sites of peritoneum (e.g. using 2-0 PDS) and the mesh will be 'parachuted' into place. Once correctly placed, the fascia above will be closed using Prolene, PDS or Nylon (surgeon preference, but excluding Vicryl). Infiltration of up to 40ml 0.25% Marcaine for infiltration into the fascial layer is recommended. The remainder of the closure will be at the surgeon's discretion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Closure
Description: The non-intervention arm for fascial closure will be the preferred technique of the surgeon without mesh reinforcement. The fascia should be closed with Prolene, PDS or nylon sutures; Vicryl should not be used for the fascia. The remainder of the closure will be at the surgeon's discretion.
Study: NCT03696641

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glazed lithium disilicate crowns
Description: glazing of IPS e.max crowns

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glazed lithium disilicate crowns
Description: glazing of IPS e.max crowns

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: polished lithium disilicate crowns
Description: polishing of IPS e.max crowns

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polished lithium disilicate crowns
Description: polishing of IPS e.max crowns
Study: NCT00427999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study: NCT04402359

Intervention type: DRUG
Intervention: meropenem
Description: meropenem one gram slowly IV infusion every 8 hours for 14 days

Intervention type: DRUG
Intervention: ceftazidime 2 grams and avibactam 500
Description: received ceftazidime 2 grams and avibactam 500 mg every 8 hours for 14 days in solution for injection(sodium chloride 9 mg/mL (0.9%), sodium chloride 4.5 mg/mL, dextrose 25 mg/mL, 0.45% sodium chloride, 2.5% dextrose and/or Lactated Ringer's solution).

Intervention type: DEVICE
Intervention: ventilator
Description: all patients selected to be ventilated for 14 days

Intervention type: DEVICE
Intervention: ventilator
Description: all patients selected to be ventilated for 14 days
Study: NCT04757324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breastfeeding education
Study: NCT01689233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRx0237 200 mg/day
Description: TRx0237 100 mg tablets will be administered twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
Study: NCT01004718

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F18
Description: Undergo FDG PET/CT scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG PET/CT scans
Study: NCT03585283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Group
Description: Manual myofascial release will be applied at prone position. Patient's upper thoracic and cervical region will be undressed. Researcher will use direct and indirect myofascial release techniques on upper thoracic and cervical region focusing on trigger point located muscles (most frequently m. trapezius)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Group
Description: Patient's upper thoracic and cervical region will be undressed. Researcher will place his hands on points that used for myofascial release however no pressure or release techniques will be used.
Study: NCT01627470

Intervention type: DEVICE
Intervention: CNAP-Monitor
Description: Continuous non-invasive arterial blood pressure recording
Study: NCT01004718

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography
Description: Undergo FDG PET/CT scans
Study: NCT00516802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KU-0059436 (AZD2281)(PARP inhibitor)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: intravenous injection over at least 20 minutes
Study: NCT00677859

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiStem®
Description: Patients will receive a single IV infusion of MultiStem® 2 days after HSCT.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiStem®
Description: Patients will receive either 3 weekly IV infusions or 5 weekly infusions of MultiStem®
Study: NCT02327013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vortioxetine 10 mg tablet
Description: Oral tablets, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vortioxetine 20 mg tablet
Description: Oral tablets, once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Oral tablets, once daily
Study: NCT00492232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon and zolpidem
Description: Ramelteon 8 mg, tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and zolpidem
Description: Ramelteon placebo-matching tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
Study: NCT04111861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Singing
Description: To investigate whether singing can help people to manage their chronic pain the applicants, working together with people with chronic pain, have developed a singing intervention, Singing for Chronic Pain (SCP). The development of the programme has been supported by Snape Moultings, an international centre for the arts which offered the team a residency to develop the programme (https://snapemaltings.co.uk/music/residencies/). The model takes a holistic approach using voice and singing, movement, sound, mindfulness and breath work to provide opportunities to connect body, voice, breath and mind. This is important given that people often use body dissociation as a way to cope with physical pain
Study: NCT02289105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mandatory active choice
Description: the mandatory active choice group, will be presented two forms at the same time. The first form will be a legally valid AD. The second form will be a declination form. Participants in the intervention arm will be required to complete, and submit either of the two forms the task.
Study: NCT00422292

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine
Description: 0.5 mL dose, intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine
Description: 0.5 mL dose, IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine
Description: 0.5 Ml dose, IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles, Mumps, Rubella and Varicella
Description: 0.5 mL dose, SC
Study: NCT00940641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: IV Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: oral dose
Study: NCT02833623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short-message-based Re-education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional education
Study: NCT03705364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fall Management program
Description: Comprehensive fall management program that develops strategies for non-ambulatory wheelchair users living with MS to develpo strategies to recover from a fall.
Study: NCT00230945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education and support intervention
Description: The patient-oriented education and support intervention (PES) is based on the Arthritis Self-Management Program, a group intervention that consists of 6 weekly 2 hour sessions shown to successfully reduce pain severity and depressive symptomatology and to enhance a sense of efficacy in managing arthritis pain and other symptoms. The couple-oriented education and support intervention (CES) is a group education and support intervention that consisted of 6 weekly 2 hour sessions attended by individuals with OA and their spouses. All components of the PES are covered in the CES using the standard format, and topics are framed as couples' issues whenever possible.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education and support intervention
Description: The patient-oriented education and support intervention (PES) is based on the Arthritis Self-Management Program, a group intervention that consists of 6 weekly 2 hour sessions shown to successfully reduce pain severity and depressive symptomatology and to enhance a sense of efficacy in managing arthritis pain and other symptoms. The couple-oriented education and support intervention (CES) is a group education and support intervention that consisted of 6 weekly 2 hour sessions attended by individuals with OA and their spouses. All components of the PES are covered in the CES using the standard format, and topics are framed as couples' issues whenever possible.
Study: NCT02384278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based CBT for alcohol problems
Description: A 12-week internet-based program based on cognitive behavior treatment (CBT) and relapse prevention
Study: NCT04266002

Intervention type: OTHER
Group type: OTHER
Intervention: Validation of Charter score for the CNS diffusion of antiretroviral drugs
Description: IHFB001 (Neuroplustrois) is a pilot study, phase IV, open-label, multicenter in Ile-de-France region, trying to demonstrate the improvement of cognitive change after treatment characterized by its better diffusion in the central nervous system. The characteristics of the change in treatment are (Cn - Ci) ≥ 3 and Cn ≥ 9, where Cn is the Charter score of the new treatment and Ci the Charter score of the initial treatment.
Study: NCT02114983

Intervention type: OTHER
Intervention: compression ultrasonography
Description: CUS in patients with a high pre-test clinical probability of DVT and/or a positive D-dimer
Study: NCT01650883

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol 50,000 IU PO every 10 days for 40 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 5,000 IU
Description: Cholecalciferol 5,000 IU PO daily for 40 days + 1200 mg Calcium Carbonate PO daily for 40 days.
Study: NCT01074697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosaprepitant dimeglumine
Description: Addition of fosaprepitant dimeglumine 150 mg IV single dose weekly (before chemotherapy) to dexamethasone and palonosetron.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline water
Study: NCT03420261

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline
Description: Fluid administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Description: Fluid administration